Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Nokes Rachael

2. Date of Event Requiring Statement (MM/DD/YYYY) 2/28/2019

3. Issuer Name and Ticker or Trading Symbol

scPharmaceuticals Inc. [SCPH]

(Last) (First) (Middle)

C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310`

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
See Remarks /

(Street)

BURLINGTON, MA 01803

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13850 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	9/17/2024	Common Stock	10455	$1.66	D
Stock Option (Right to Buy)	⁽³⁾	3/13/2025	Common Stock	10455	$8.12	D
Stock Option (Right to Buy)	⁽⁴⁾	4/17/2027	Common Stock	6426	$3.81	D
Stock Option (Right to Buy)	⁽⁵⁾	1/17/2028	Common Stock	17000	$12.23	D
Stock Option (Right to Buy)	⁽⁶⁾	7/17/2028	Common Stock	13850	$4.88	D

Explanation of Responses:
(1)	Consists of a restricted stock unit award made pursuant to the scPharmaceuticals Inc. 2017 Stock Option and Incentive Plan. The restricted stock units vest in equal annual installments over a two-year period beginning on February 25, 2019. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in no event later than two and one-half months after the end of the year in which such vesting date occurs.
(2)	This option is fully vested.
(3)	25% of these shares vested on March 13, 2016 then in 36 equal monthly installments thereafter.
(4)	25% of these shares vested on April 17, 2018 then in 36 equal monthly installments thereafter.
(5)	25% of these shares vested on January 17, 2019 then in 36 equal monthly installments thereafter.
(6)	25% of these shares shall vest on July 17, 2019 then in 36 equal monthly installments thereafter.

Remarks:
SVP, Finance; Principal Accounting Officer

Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Nokes Rachael C/O SCPHARMACEUTICALS INC. 2400 DISTRICT AVENUE, SUITE 310` BURLINGTON, MA 01803			See Remarks

Signatures
/s/ John Tucker, Attorney-in-Fact		3/6/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.